

**Date:** July 10, 2025

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) - Acquisition of 6730 Equity Shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals - Subsidiary of the Company**

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, we would like to inform that as per the approval accorded by the Management Committee of Board of Directors of the Senores Pharmaceuticals Limited (“the Company or “the Purchaser”), in their meeting held today i.e. July 10, 2025, the Company has entered into the Share Purchase Agreement (“SPA”) with one of the shareholders (Public Category) of Havix Group Inc. D/B/A Aavis Pharmaceuticals (“Havix” or “the Target Company”) for acquisition of 6730 (Six Thousand Seven Hundred Thirty) equity shares of Havix i.e. 2.97% of the total paid up share capital of Havix and subject to the terms and conditions as mentioned in the SPA.

Further, post the aforesaid acquisition the aggregate shareholding of the Company (along with the shareholding of its wholly owned subsidiary – Senores Pharmaceuticals Inc.) in Havix will increase from 70.07% to 73.04%.

We have enclosed herewith the details required under Regulation 30 read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as **Annexure -1**.

We request you to take the above information on record.

Thanking you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

Encl.: As above

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

**Disclosure under Regulation 30(6) read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

Sr. No.	Particulars	Description						
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Havix Group Inc. D/B/A Aavis Pharmaceuticals ("Havix") is currently engaged in the business of developing, manufacturing and supplying of various finished formulations.  The turnover of Havix for the financial year ended March 31, 2025 was USD 19,869,291.						
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The shares of Havix are being acquired from one of the shareholders of the Havix (Public Category) and hence it does not fall under the ambit of related party transaction.  The transaction is being done at arm's length basis.						
3.	Industry to which the entity being acquired belongs	Pharmaceuticals						
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Senores Pharmaceuticals Limited, along with the its wholly owned subsidiary – Senores Pharmaceuticals Inc. at present holds 70.07% of equity shares of Havix and the aforesaid acquisition of 6730 equity shares is being done to consolidate the holding of the Company in Havix - a subsidiary of the Company.						
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Requisite approvals under Foreign Exchange Management Act, 1999 have been applied for.						
6.	Indicative time period for completion of the acquisition	Within period 30 (Thirty) days from the date of execution of SPA i.e. July 10, 2025.						
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash						
8.	Cost of acquisition or the price at which the shares are acquired	USD 181 per equity share.						
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	6730 (Six Thousand Seven Hundred Thirty) equity shares constituting 2.97%, of the total paid up share capital of the Target Company.						
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Havix was incorporated under the laws of the State of Delaware on February 17, 2015. Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations.  The turnover of Havix for last 3 years is given below: <i>(Amount in USD)</i> <table border="1" data-bbox="857 1581 1414 1654"> <thead> <tr> <th>Mar-23</th> <th>Mar-24</th> <th>Mar-25</th> </tr> </thead> <tbody> <tr> <td>8,814,761</td> <td>14,440,414</td> <td>19,869,291</td> </tr> </tbody> </table> Country of presence: United States of America	Mar-23	Mar-24	Mar-25	8,814,761	14,440,414	19,869,291
Mar-23	Mar-24	Mar-25						
8,814,761	14,440,414	19,869,291						

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

 W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263